Cell culture, a pivotal technique in cellular and molecular biology, is experiencing significant growth owing to its indispensable role in understanding cell physiology and biochemistry. The cell culture market is thriving, driven by increased awareness and its utilization in producing vital biological compounds like recombinant proteins and antibodies. Researchers and biopharmaceutical companies are increasingly adopting cell culture techniques for vaccine development, including vaccines for diseases such as polio, smallpox, hepatitis, rubella, and chickenpox. The rising prevalence of chronic and infectious diseases globally, coupled with the surging demand for vaccines, is poised to propel the cell culture market during the forecast period.
According to the World Health Organization (WHO), chronic diseases claimed 41 million lives worldwide in 2021. Cardiovascular disease tops the list, causing 17.9 million deaths annually, followed by cancer (9.3 million), respiratory disorders (4.1 million), and diabetes (1.5 million). The substantial toll of chronic diseases has spurred market leaders to enhance and innovate biologics products. Additionally, the increasing incidence of infectious diseases and the looming threat of pandemics are expected to drive global vaccine demand. Cell culture has emerged as a vital component of vaccine production in the pharmaceutical industry, with cell culture-based flu vaccines gaining regulatory approval in multiple countries. Rising awareness of the benefits of cell culture-based vaccines and the approval of several such vaccines worldwide are key drivers of the cell culture markets growth.
Furthermore, increased investments in research and development, along with the establishment of new manufacturing facilities for biopharmaceutical mass production, will create growth opportunities in the global cell culture market. For example, Fujifilm Corporation invested over 200 billion yen in January 2021 to establish a large-scale cell culture production plant for biopharmaceuticals in the United States, accelerating the growth of their biopharmaceutical contract development and manufacturing business.
Drug Screening & Development Segment Application to Lead the Cell Culture Market
The drug screening & development segment is expected to be the fastest-growing sector in the cell culture market. Factors driving this growth include the rising prevalence of chronic diseases, increasing public awareness of biopharmaceuticals, and the surge in biopharmaceutical production and consumption worldwide. The COVID-19 outbreak has propelled drug screening and development to the forefront of the biotechnology industry, with numerous companies and research organizations actively working on developing drugs and vaccines for contagious coronavirus infections. Collaborative efforts by entities like Entos Pharmaceuticals, Roivant Sciences, Altimmune, and Biopharma are expected to fuel the growth of this segment. Moreover, the rapid expansion of the biopharmaceutical contract manufacturing market in developed and developing markets will further support this segments growth.
Increased Healthcare Expenditure and Presence of Leading Market Players to Drive Growth of North American Cell Culture Market
North America continues to lead the cell culture market and is poised to maintain its dominant position. This is primarily attributed to the growing demand for personalized medicine and the presence of key market players. Additionally, increased healthcare expenditure contributes to the growth of the cell culture market in North America, with the United States serving as a global hub for drug research and development. Government and non-government organizations in the U.S. allocate billions of dollars annually to medical research. For example, the National Institutes of Health (NIH) alone invests approximately USD 41.7 billion in medical research each year.
Technological advancements in cell culture instruments and equipment have also played a pivotal role in driving growth in this region. The U.S. healthcare and life science industries have been early adopters of cell culture techniques, resulting in the countrys substantial market share. The ongoing research and expansion of the biopharmaceutical sector in the U.S. are key drivers of the cell culture market. The demand for creative solutions to meet the evolving needs of local customers has led to collaborative initiatives, such as Mammoth Biosciences partnership with Bayer in January 2022 to develop in vivo gene editing therapeutics using Mammoths CRISPR system.
Moreover, the Asia Pacific region is experiencing rapid growth in the cell culture market, driven by increased biopharmaceutical research, strong government support, and the expansion of biopharmaceutical manufacturing. China and India, with their low manufacturing costs, have attracted pharmaceutical and biotech companies, resulting in increased production capacity. In India, technological advancements, the development of regenerative therapies, and the rising incidence of hereditary and chronic disorders are propelling the cell culture market. Government initiatives to align with the evolving trends in drug development, such as the inclusion of cell culture-derived products in the definition of new drugs, as seen in the Union Health Ministry of Indias amendment to the New Drugs & Clinical Trials Act in January 2022, are expected to further boost the market.
Global Cell Culture Market: Competitive Landscape
Companies in the cell culture market are continuously innovating and forging collaborations, alliances, and partnership agreements. For instance, Thermo Fisher Scientific Inc. introduced the Gibco Cell Therapy Systems (CTS) NK-Xpander Medium in October 2021, enabling large-scale growth and culture of functional natural killer (NK) cells. In July 2021, Sartorius AG announced the acquisition of cell culture specialist Xell AG to expand its product offerings in manufacturing viral vectors and media analytics.
Key players in the cell culture market include Merck KGaA, ANGUS Chemical Company, Thermo Fisher Scientific Inc., Biospherix Ltd., Danaher Corporation, SeraCare Life Sciences Inc., Corning Incorporated, Adolf Kuhner AG, Eppendorf AG, Meissner Filtration Products Inc., Lonza Group AG, Cellexus, PromoCell GmbH, Pan-Biotech GmbH, Caisson Laboratories Inc., Getinge AB, Solida Biotech GmbH, Miltenyi Biotech, Sartorius AG, Becton, HiMedia Laboratories, Agilent Technologies Inc., FUJIFILM Irvine Scientific, Inc., STEMCELL Technologies Inc., and InvivoGen.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/cell-culture-market
Our Blogs:
https://hackmd.io/@E4v1isUnROG4-prBVaQQGw/H1dK7D6Ch
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of
services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
This press release first seen on Brilad
COMTEX_442039246/2840/2023-10-17T19:17:26
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No journalist was involved in the writing and production of this article.
